Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an update.
Australian Clinical Labs Limited has reached an agreement with the Australian Information Commissioner to resolve a civil penalty proceeding related to a cyberattack on Medlab Pathology, which occurred shortly after ACL acquired the business. The agreement includes a proposed penalty of $5.8 million and a contribution of $400,000 towards legal costs, pending Federal Court approval. The cyberattack did not affect ACL’s systems, and the company has since integrated Medlab’s IT systems into its own robust cybersecurity framework. This resolution allows ACL to focus on its strategic goals and continue delivering high-quality pathology services.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs (ACL) is a prominent private provider of pathology services in Australia. The company operates NATA accredited laboratories that conduct a wide range of pathology tests for various clients, including doctors, specialists, patients, hospitals, and corporate clients. ACL is recognized as one of the largest private hospital pathology businesses in the country, focusing on combining skilled personnel and leadership with innovative technologies to enhance decision-making and improve patient outcomes.
Average Trading Volume: 935,991
Technical Sentiment Signal: Sell
Current Market Cap: A$487.5M
For an in-depth examination of ACL stock, go to TipRanks’ Overview page.